EUVIMEDEUVIMED entdecken
Klinische Studie (Phase II)Klinische Studie (Phase III)Randomisierte kontrollierte Studie

Efficacy and Safety of an mRNA-Based RSV PreF Vaccine in Older Adults

Eleanor Wilson, Jaya Goswami, Abdullah H Baqui, Pablo A Doreski, Gonzalo Perez-Marc, Khalequ Zaman, Jorge Monroy, Christopher J A Duncan, Mugen Ujiie, Mika Rämet, Lina Pérez-Breva, Ann R Falsey und 22 weitere

New England Journal of Medicine · 14.12.2023 · 389 (24) · 2233-2244

DOI: 10.1056/nejmoa2307079 ↗

Kurz gefasst

Klinische Studie (Phase II) in der Zeitschrift New England Journal of Medicine, erschienen am 14.12.2023. Verfasst von Eleanor Wilson und 33 weiteren Autor:innen. Beteiligte Einrichtung: From Moderna, Cambridge, MA (E.W., J.G., R. Dhar, L.W., J.D., P.G., A.K., L.L., S.M., R.M., C.A.P., A.K.S., B.J.K., F.S., W.H., C.R., K.S., S.K.S., C…. Hauptthemen laut MEDLINE: Respiratory Syncytial Virus Infections, Respiratory Syncytial Virus, Human, mRNA Vaccines, Respiratory Syncytial Virus Vaccines. Die Arbeit wurde bisher 556-mal zitiert (Crossref) und nennt 35 Literaturangaben. Gefördert von: Medical Research Council, Moderna, Moderna, Inc..

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND: Respiratory syncytial virus (RSV) can cause substantial morbidity and mortality among older adults. An mRNA-based RSV vaccine, mRNA-1345, encoding the stabilized RSV prefusion F glycoprotein, is under clinical investigation. METHODS: In this ongoing, randomized, double-blind, placebo-controlled, phase 2-3 trial, we randomly assigned, in a 1:1 ratio, adults 60 years of age or older to receive one dose of mRNA-1345 (50 μg) or placebo. The two primary efficacy end points were the prevention of RSV-associated lower respiratory tract disease with at least two signs or symptoms and with at least three signs or symptoms. A key secondary efficacy end point was the prevention of RSV-associated acute respiratory disease. Safety was also assessed. RESULTS: Overall, 35,541 participants were assigned to receive the mRNA-1345 vaccine (17,793 participants) or placebo (17,748). The median follow-up was 112 days (range, 1 to 379). The primary analyses were conducted when at least 50% of the anticipated cases of RSV-associated lower respiratory tract disease had occurred. Vaccine efficacy was 83.7% (95.88% confidence interval [CI], 66.0 to 92.2) against RSV-associated lower respiratory tract disease with at least two signs or symptoms and 82.4% (96.36% CI, 34.8 to 95.3) against the disease with at least three signs or symptoms. Vaccine efficacy was 68.4% (95% CI, 50.9 to 79.7) against RSV-associated acute respiratory disease. Protection was observed against both RSV subtypes (A and B) and was generally consistent across subgroups defined according to age and coexisting conditions. Participants in the mRNA-1345 group had a higher incidence than those in the placebo group of solicited local adverse reactions (58.7% vs. 16.2%) and of systemic adverse reactions (47.7% vs. 32.9%); most reactions were mild to moderate in severity and were transient. Serious adverse events occurred in 2.8% of the participants in each trial group. CONCLUSIONS: A single dose of the mRNA-1345 vaccine resulted in no evident safety concerns and led to a lower incidence of RSV-associated lower respiratory tract disease and of RSV-associated acute respiratory disease than placebo among adults 60 years of age or older. (Funded by Moderna; ConquerRSV ClinicalTrials.gov number, NCT05127434.).

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Respiratory Syncytial Virus InfectionsRespiratory Syncytial Virus, HumanmRNA VaccinesRespiratory Syncytial Virus VaccinesAgedHumansAntibodies, ViralDouble-Blind MethodRespiratory Tract DiseasesTreatment OutcomeMiddle Aged

Substanzen

Antibodies, ViralmRNA VaccinesRespiratory Syncytial Virus Vaccines

Autor:innen und Institutionen

  • From Moderna, Cambridge, MA (E.W., J.G., R. Dhar, L.W., J.D., P.G., A.K., L.L., S.M., R.M., C.A.P., A.K.S., B.J.K., F.S., W.H., C.R., K.S., S.K.S., C.A.S., J.M.M., R. Das, G.L.C.); Johns Hopkins Bloomberg School of Publ…

ORCID-Profile: Lauren Wilson

Förderung

  • Medical Research Council
  • Moderna
  • Moderna, Inc.

Zitieren

APA

Wilson, E., Goswami, J., Baqui, A. H., Doreski, P. A., Perez-Marc, G., Zaman, K., Monroy, J., Duncan, C. J. A., Ujiie, M., Rämet, M., Pérez-Breva, L., Falsey, A. R., Walsh, E. E., Dhar, R., Wilson, L., Du, J., Ghaswalla, P., Kapoor, A., Lan, L., …, & ConquerRSV Study Group (2023). Efficacy and Safety of an mRNA-Based RSV PreF Vaccine in Older Adults. New England Journal of Medicine, 389(24), 2233-2244. https://doi.org/10.1056/nejmoa2307079

Vancouver

Wilson E, Goswami J, Baqui AH, Doreski PA, Perez-Marc G, Zaman K, et al. Efficacy and Safety of an mRNA-Based RSV PreF Vaccine in Older Adults. New England Journal of Medicine. 2023;389(24):2233-2244. doi:10.1056/nejmoa2307079

BibTeX
@article{Wilson2023,
  author = {Wilson, Eleanor and Goswami, Jaya and Baqui, Abdullah H and Doreski, Pablo A and Perez-Marc, Gonzalo and Zaman, Khalequ and Monroy, Jorge and Duncan, Christopher J A and Ujiie, Mugen and Rämet, Mika and Pérez-Breva, Lina and Falsey, Ann R and Walsh, Edward E and Dhar, Rakesh and Wilson, Lauren and Du, Jiejun and Ghaswalla, Parinaz and Kapoor, Archana and Lan, Lan and Mehta, Shraddha and Mithani, Runa and Panozzo, Catherine A and Simorellis, Alana K and Kuter, Barbara J and Schödel, Florian and Huang, Wenmei and Reuter, Caroline and Slobod, Karen and Stoszek, Sonia K and Shaw, Christine A and Miller, Jacqueline M and Das, Rituparna and Chen, Grace L and ConquerRSV Study Group, ConquerRSV Study Group},
  title = {Efficacy and Safety of an mRNA-Based RSV PreF Vaccine in Older Adults},
  journal = {New England Journal of Medicine},
  year = {2023},
  volume = {389},
  number = {24},
  pages = {2233--2244},
  doi = {10.1056/nejmoa2307079}
}
Kostenlos starten →